Does Rallies show Form 4 insider transactions for JAZZ?

Yes. Rallies tracks JAZZ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is JAZZ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.

JAZZ (Jazz Pharmaceuticals, Inc.) Stock Analysis - Insider Trades

Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of May 21, 2026, JAZZ trades at $237.51 with a market cap of $14.40B and a P/E ratio of 26.45. JAZZ moved +0.70% today. Year to date, JAZZ is +37.05%; over the trailing twelve months it is +115.29%. Its 52-week range spans $95.49 to $242.18. Analyst consensus is strong buy with an average price target of $241.43. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading JAZZ stock inside the company?

Recent JAZZ insider activity includes COZADD BRUCE C sold 6.00K, COZADD BRUCE C sold 3.68K, COZADD BRUCE C sold 2.29K, COZADD BRUCE C sold 24, and Carr Patricia sold 1.29K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

JAZZ Key Metrics

Key financial metrics for JAZZ
Metric	Value
Price	$237.51
Market Cap	$14.40B
P/E Ratio	26.45
EPS	$9.06
Dividend Yield	0.00%
52-Week High	$242.18
52-Week Low	$95.49
Volume	36
Avg Volume	0
Revenue (TTM)	$4.07B
Net Income	$560.12M
Gross Margin	0.00%

Recent JAZZ Insider Trades

COZADD BRUCE C sold 6.00K (~$1.22M) on May 1, 2026.
COZADD BRUCE C sold 3.68K (~$700.78K) on Apr 1, 2026.
COZADD BRUCE C sold 2.29K (~$437.63K) on Apr 1, 2026.
COZADD BRUCE C sold 24 (~$4.60K) on Apr 1, 2026.
Carr Patricia sold 1.29K (~$235.44K) on Mar 9, 2026.

Latest JAZZ News

Jazz Pharmaceuticals jumps on Q1 revenue surge, EPS beat, and reaffirmed 2026 outlook — May 6, 2026
Jazz Pharmaceuticals Reports 19% Revenue Growth to $1.1B, Zanidatamab Granted Priority Review — May 5, 2026
Jazz Pharmaceuticals rises as ASCO 2026 Ziihera data looms, analyst optimism builds — Apr 27, 2026
Jazz Pharmaceuticals Gets FDA Priority Review, August 25 PDUFA for Ziihera in HER2+ GEA — Apr 27, 2026
Jazz Pharmaceuticals Sets May 5 Q1 Report, Showcases ASCO Data for Ziihera and Zepzelca — Apr 21, 2026

JAZZ Analyst Consensus

15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $241.43.

Common questions about JAZZ

Who is trading JAZZ stock inside the company?: Recent JAZZ insider activity includes COZADD BRUCE C sold 6.00K, COZADD BRUCE C sold 3.68K, COZADD BRUCE C sold 2.29K, COZADD BRUCE C sold 24, and Carr Patricia sold 1.29K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for JAZZ?: Yes. Rallies tracks JAZZ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is JAZZ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.